86 related articles for article (PubMed ID: 26256458)
1. Long-term remission in idiopathic Castleman's disease with tocilizumab followed by consolidation with high-dose melphalan--two case studies.
Jerkeman M; Lindén O
Eur J Haematol; 2016 May; 96(5):541-3. PubMed ID: 26256458
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of aggressive HIV-associated multicentric Castleman's disease: a case report.
Flejsierowicz M; Ahmed MS; Kotov P; Cheng YC
WMJ; 2008 Jul; 107(4):191-4. PubMed ID: 18702436
[TBL] [Abstract][Full Text] [Related]
3. Remissions of different quality following rituximab, tocilizumab and rituximab, and allogeneic stem cell transplantation in a patient with severe idiopathic multicentric Castleman's disease.
Angenendt L; Kerkhoff A; Wiebe S; Mikesch JH; Rudat A; Wötzel F; Wenning C; Schliemann C; Kessler T; Schäfers M; Wardelmann E; Stelljes M; Berdel WE
Ann Hematol; 2015 Jul; 94(7):1241-3. PubMed ID: 25791243
[No Abstract] [Full Text] [Related]
4. Successful tocilizumab treatment in a patient with human herpesvirus 8-positive and human immunodeficiency virus-negative multicentric Castleman's disease of plasma cell type nonresponsive to rituximab-CVP therapy.
Műzes G; Sipos F; Csomor J; Sréter L
APMIS; 2013 Jul; 121(7):668-74. PubMed ID: 23163599
[TBL] [Abstract][Full Text] [Related]
5. A case of multicentric Castleman's disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody.
Gholam D; Vantelon JM; Al-Jijakli A; Bourhis JH
Ann Hematol; 2003 Dec; 82(12):766-8. PubMed ID: 12898190
[TBL] [Abstract][Full Text] [Related]
6. Long-term remission in HIV-negative patients with multicentric Castleman's disease using rituximab.
Ide M; Kawachi Y; Izumi Y; Kasagi K; Ogino T
Eur J Haematol; 2006 Feb; 76(2):119-23. PubMed ID: 16405432
[TBL] [Abstract][Full Text] [Related]
7. Pulmonary manifestations of multicentric Castleman's disease in HIV infection: a clinical, biological and radiological study.
Guihot A; Couderc LJ; Agbalika F; Galicier L; Bossi P; Rivaud E; Scherrer A; Zucman D; Katlama C; Oksenhendler E
Eur Respir J; 2005 Jul; 26(1):118-25. PubMed ID: 15994398
[TBL] [Abstract][Full Text] [Related]
8. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide.
Lee FC; Merchant SH
Am J Hematol; 2003 May; 73(1):48-53. PubMed ID: 12701121
[TBL] [Abstract][Full Text] [Related]
9. Successful Treatment of TAFRO Syndrome, a Variant of Multicentric Castleman's Disease, with Cyclosporine A: Possible Pathogenetic Contribution of Interleukin-2.
Konishi Y; Takahashi S; Nishi K; Sakamaki T; Mitani S; Kaneko H; Mizutani C; Ukyo N; Hirata H; Tsudo M
Tohoku J Exp Med; 2015 Aug; 236(4):289-95. PubMed ID: 26250536
[TBL] [Abstract][Full Text] [Related]
10. A case of multicentric Castleman's disease in HIV infection with the rare complication of acquired angioedema.
Fernando I; Scott G
Int J STD AIDS; 2014 Jun; 25(7):523-5. PubMed ID: 24352125
[TBL] [Abstract][Full Text] [Related]
11. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV-positive men: a case series.
Bestawros A; Michel R; Séguin C; Routy JP
Am J Hematol; 2008 Jun; 83(6):508-11. PubMed ID: 18027834
[TBL] [Abstract][Full Text] [Related]
12. [Effectiveness of long term administration of humanized anti-interleukin-6 receptor antibody (tocilizumab) for multicentric Castleman's disease with pulmonary involvement].
Akahane D; Kimura Y; Sumi M; Sashida G; Gotoh A; Miyazawa K; Ohyashiki K
Rinsho Ketsueki; 2006 Aug; 47(8):748-52. PubMed ID: 16986713
[TBL] [Abstract][Full Text] [Related]
13. Aggressive angiofollicular lymph node hyperplasia (Castleman's disease) treated with high dose melphalan and autologous bone marrow transplantation.
Repetto L; Jaiprakash MP; Selby PJ; Gusterson BA; Williams HJ; McElwain TJ
Hematol Oncol; 1986; 4(3):213-7. PubMed ID: 3533746
[TBL] [Abstract][Full Text] [Related]
14. Treatment of multicentric Castleman's disease complicated by the development of non-Hodgkin's lymphoma with high-dose chemotherapy and autologous peripheral stem-cell support.
Advani R; Warnke R; Rosenberg S
Ann Oncol; 1999 Oct; 10(10):1207-9. PubMed ID: 10586338
[TBL] [Abstract][Full Text] [Related]
15. Favorable consolidative effect of high-dose melphalan and total-body irradiation followed by autologous peripheral blood stem cell transplantation after rituximab-containing induction chemotherapy with in vivo purging in relapsed or refractory follicular lymphoma.
Kato H; Taji H; Ogura M; Kagami Y; Oki Y; Tsujimura A; Fuwa N; Kodaira T; Seto M; Yamamoto K; Morishima Y
Clin Lymphoma Myeloma; 2009 Dec; 9(6):443-8. PubMed ID: 19951884
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of rituximab in an aggressive form of multicentric Castleman disease associated with immune phenomena.
Ocio EM; Sanchez-Guijo FM; Diez-Campelo M; Castilla C; Blanco OJ; Caballero D; San Miguel JF
Am J Hematol; 2005 Apr; 78(4):302-5. PubMed ID: 15795923
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial.
Gérard L; Bérezné A; Galicier L; Meignin V; Obadia M; De Castro N; Jacomet C; Verdon R; Madelaine-Chambrin I; Boulanger E; Chevret S; Agbalika F; Oksenhendler E
J Clin Oncol; 2007 Aug; 25(22):3350-6. PubMed ID: 17664482
[TBL] [Abstract][Full Text] [Related]
18. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
19. [Retrospective study of multicentric Castleman's disease treated with CEOD chemotherapy].
Wang HH; Yao K; Li YC
Zhonghua Xue Ye Xue Za Zhi; 2012 Jan; 33(1):56-8. PubMed ID: 22575196
[No Abstract] [Full Text] [Related]
20. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
